Pneumocystis carinii pneumonia in pregnancy

Citation
H. Ahmad et al., Pneumocystis carinii pneumonia in pregnancy, CHEST, 120(2), 2001, pp. 666-671
Citations number
24
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CHEST
ISSN journal
00123692 → ACNP
Volume
120
Issue
2
Year of publication
2001
Pages
666 - 671
Database
ISI
SICI code
0012-3692(200108)120:2<666:PCPIP>2.0.ZU;2-4
Abstract
Objective: To report five new cases of Pneumocystis carinii pneumonia (PCP) and to review and analyze thee existing reports on the subject. Method: Five new cases of PCP during pregnancy are described. The cases, ca se series, and related articles on the subject in the English language were identified through a comprehensive MEDLINE search and reviewed. Results: More than 80% of women with AIDS are of reproductive age, and PCP is the most common cause of AIDS-related death in pregnant women in the Uni ted States. Among 22 reviewed cases, the mortality rate was 50% (11 of 22 p atients), which is higher than that usually reported for HIV-infected indiv iduals with PCP. Respiratory failure developed in 13 patients (59%), and me chanical ventilation was therefore required, and the survival rate in patie nts requiring mechanical ventilation was 31%. Maternal and fetal outcomes w ere better in cases of PCP during the third trimester of the pregnancy. A v ariety of treatment regimens were used, including sulfamethoxazole-trimetho prim (SXT) alone or in combination with pentamidine, steroids, and eflornit hine. The survival rate in patients treated with SXT alone was 71% (5 of 7 patients) and for those treated,vith SXT and steroids was 60% (3 of 5 patie nts), with an overall survival rate in both groups of 66.6% (S of 12 patien ts). Conclusion: PCP has a more aggressive course during pregnancy, with increas ed morbidity and mortality. Maternal and fetal outcomes remain dismal. Trea tment with SXT, compared to other therapies, may result in an improved outc ome. Withholding appropriate PCP prophylaxis may adversely affect maternal and fetal outcomes.